These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23280702)

  • 1. Uncertainty and the decision maker: assessing and managing the risk of undesirable outcomes.
    Gafni A; Walter S; Birch S
    Health Econ; 2013 Nov; 22(11):1287-94. PubMed ID: 23280702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation.
    Krucien N; Pelletier-Fleury N; Gafni A
    Pharmacoeconomics; 2019 Mar; 37(3):407-417. PubMed ID: 30499065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
    Siebert U; Rochau U; Claxton K
    Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations.
    Sendi P; Al MJ; Gafni A; Birch S
    Soc Sci Med; 2004 May; 58(10):1853-5. PubMed ID: 15020003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.
    Elbasha EH
    Health Econ; 2005 May; 14(5):457-70. PubMed ID: 15386661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment in the cost-disutility plane.
    Eckermann S; Briggs A; Willan AR
    Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Portfolio evaluation of health programs: a reply to Sendi et al.
    Bridges JF; Terris DD
    Soc Sci Med; 2004 May; 58(10):1849-51. PubMed ID: 15020002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Setting the most robust effluent level under severe uncertainty: application of information-gap decision theory to chemical management.
    Yokomizo H; Naito W; Tanaka Y; Kamo M
    Chemosphere; 2013 Nov; 93(10):2224-9. PubMed ID: 24125713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addressing risk preferences in cost-effectiveness analyses.
    Zivin JG; Bridges JF
    Appl Health Econ Health Policy; 2002; 1(3):135-9. PubMed ID: 14619264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty.
    Sendi P; Al MJ
    Soc Sci Med; 2003 Sep; 57(6):969-74. PubMed ID: 12878098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using probabilistic terrorism risk modeling for regulatory benefit-cost analysis: application to the Western hemisphere travel initiative in the land environment.
    Willis HH; LaTourrette T
    Risk Anal; 2008 Apr; 28(2):325-39. PubMed ID: 18419652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining the cost of reducing uncertainty with the selection of risk assessment models for remediation decision of site contamination.
    Chen YC; Ma HW
    J Hazard Mater; 2007 Mar; 141(1):17-26. PubMed ID: 16926066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decision support tool to prioritize risk management options for contaminated sites.
    Sorvari J; Seppälä J
    Sci Total Environ; 2010 Mar; 408(8):1786-99. PubMed ID: 20138649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
    Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
    Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expected value of information and decision making in HTA.
    Eckermann S; Willan AR
    Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective.
    Forster M; Pertile P
    Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating Portfolio Uncertainty in Decision Rules for Healthcare Resource Allocation.
    Sendi P; Gafni A; Birch S; Walter SD
    Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33799361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.